REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT05205850
- Locations
- 🇨🇳
The first affiliated hospital, zhejiang universtity school of medicine, Hangzhou, Zhejiang, China
🇨🇳Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
- Conditions
- Advanced MelanomaMelanoma, Stage IIHER2-positive
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05135715
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Zhejiang cancer hospital, Hangzhou, Zhejiang, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04965519
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, China
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
- Conditions
- Unresectable Solid TumorMetastatic Solid TumorLocally Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT04914117
- Locations
- 🇦🇺
Remegen Site #14, Bedford Park, South Australia, Australia
🇦🇺Remegen Site #12, Macquarie Park, New South Wales, Australia
🇦🇺Remegen Site #13, Frankston, Victoria, Australia
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
- Conditions
- IgA Nephropathy
- Interventions
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT04905212
- Locations
- 🇺🇸
Remegen Site #5, Los Angeles, California, United States
🇺🇸Remegen Site #13, Los Angeles, California, United States
🇺🇸Remegen Site #14, Los Angeles, California, United States
Evaluation of RC28-E Injection in Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- Biological: intravitreal injection of RC28-EBiological: Conbercept
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT04782115
- Locations
- 🇨🇳
People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Evaluation of RC28-E Injection in Diabetic Retinopathy
- Conditions
- Diabetic Retinopathy
- Interventions
- Biological: RC28-E injection
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04782128
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Conditions
- Gastric CancerHER2 Overexpressing Gastric Carcinoma
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 351
- Registration Number
- NCT04714190
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Biological: RC18 240mgBiological: RC18 160mg
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04625153
- Locations
- 🇨🇳
the Third Affiliated Hospital,Sun Yat-Sen University, Guangzhou, Guangdong, China
A Study of RC108-ADC in Subjects with Advanced Malignant Solid Tumors
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04617314
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China